This paper is only available as a PDF. To read, Please Download here.
Solid cancers are highly refractory to conventional therapies and urgently need alternative
treatments. We showed in previous work that tumour-directed dendritic cell vaccines
(DC) when applied during oncolytic virus-mediated tumour inflammation (referred to
as ODC) successfully triggers a CD8 T-cell response against model-antigens in mice.
The central aim of this study was to identify tumour-associated neoantigens suitable
to investigate the efficacy of ODC treatment. Therefore, we performed transcriptomic
sequencing and epitope prediction leading to detection of the neoepitope Ndufs1-V491A
which is present in the NSCLC cell line CMT64 and the HCC cell line Hepa1.6. Elispot
assays showed that intratumoural infection of subcutaneous (s.c.) CMT64-tumours on
C57Bl/6 mice with oncolytic adenovirus induced significant T-cell responses against
Ndufs1-V491A that were significantly less reactive to the wild type peptide. FACS
analyses demonstrated neoepitope-specific T-cell responses after Ndufs1-V491A-directed
DC vaccination that were additionally amplified by ODC. This ODC treatment was furthermore
capable of inducing neoantigen-specific cytotoxicity as shown by in vivo CTL analyses. Finally, we established an Ndufs1-V491A-specific pentamer that allows
functional investigations on Ndufs1-V491A-specific CD8 cells.
In summary, we established the neoantigen Ndufs1-V491A which is well suited to investigate
tumour-directed CD8 T-cells raised by various immunotherapeutic approaches in murine
tumour models.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
